Jason Kang

Jason Kang is the CEO and Co-Founder of Kinnos Inc., a New York-based company that aims to raise the standard of infectious disease decontamination to protect healthcare workers, patients, and the general public. Their first product, Highlight®, is a patent-pending additive that greatly improves visibility, coverage, and end-user compliance of disinfectants. Highlight® is used by HazMat and biosafety units, was a grantee of the USAID Fighting Ebola Grand Challenge, and has been field-tested by NGOs and healthcare workers in Liberia, Guinea, and Haiti. Kinnos has additionally been recognized as winners of the Lemelson-MIT Student Prize, Collegiate Inventors Competition, and Columbia Venture Competition, and has been featured in the Wall Street Journal, NPR, Scientific American, and PBS NewsHour.

Prior to Kinnos, Jason served as Vice President of Engineering at Jibon Health Technologies, where he invented a low-cost medical device to treat postpartum hemorrhage. The device was awarded a $250k Saving Lives at Birth Grand Challenge seed grant by USAID, Bill & Melinda Gates Foundation, Grand Challenges Canada, UKAID, and Norwegian Ministry of Foreign Affairs, and was brought to clinical trials in Bangladesh.

For his innovative work in global health, Jason served as a U.S. Delegate at the Global Entrepreneurship Summit, was named to Forbes 30 Under 30 in Healthcare, and is a Fellow of the Kairos Society. In 2016, Jason received his B.S. in Biomedical Engineering from Columbia University, where he was an Egleston Scholar and graduated Tau Beta Pi.